Exploring retroperitoneal fibrosis: Insights, challenges, and treatment approaches.

Ormond’s disease Retroperitoneal fibrosis idiopathic ureterolysis

Journal

Urologia
ISSN: 1724-6075
Titre abrégé: Urologia
Pays: United States
ID NLM: 0417372

Informations de publication

Date de publication:
13 Sep 2024
Historique:
medline: 15 9 2024
pubmed: 15 9 2024
entrez: 13 9 2024
Statut: aheadofprint

Résumé

Retroperitoneal fibrosis (RPF) is a rare fibro-inflammatory condition characterized by abnormal tissue growth around the abdominal aorta and iliac arteries, usually encasing adjacent structures like the ureters. Its etiology remains most of the time idiopathic, but secondary causes, including malignancies and medication use, account for a minority of cases. This review aims to consolidate recent advancements in understanding RPF, focusing on its pathophysiology, diagnosis, and treatment. Literature search was conducted using databases like PubMed, with emphasis on recent publications. Biomarkers such as elevated CRP levels and imaging techniques like CT scans and MRI play pivotal roles in diagnosis and monitoring. Medical management primarily revolves around corticosteroids, with adjunctive therapies like tamoxifen and immunosuppressants showing promise. Surgical intervention, typically ureterolysis, becomes necessary in cases of urinary tract obstruction. This review studies the importance of a comprehensive approach to RPF management, integrating medical and surgical modalities for optimal patient outcomes.

Identifiants

pubmed: 39268704
doi: 10.1177/03915603241270453
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3915603241270453

Déclaration de conflit d'intérêts

Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Anass Mehedra (A)

Urology Department B, CHU Ibn Sina, Rabat, Morocco.

Youssef Maachi (Y)

Urology Department B, CHU Ibn Sina, Rabat, Morocco.

Mouftah Babty (M)

Urology Department B, CHU Ibn Sina, Rabat, Morocco.

Amine Slaoui (A)

Urology Department B, CHU Ibn Sina, Rabat, Morocco.

Tarik Karmouni (T)

Urology Department B, CHU Ibn Sina, Rabat, Morocco.

Khalid Elkhader (K)

Urology Department B, CHU Ibn Sina, Rabat, Morocco.

Abdellatif Koutani (A)

Urology Department B, CHU Ibn Sina, Rabat, Morocco.

Ahmed Andaloussi Ibenattya (AA)

Urology Department B, CHU Ibn Sina, Rabat, Morocco.

Classifications MeSH